Fulcrum Therapeutics (NASDAQ:FULC) Announces Earnings Results, Hits Estimates

Fulcrum Therapeutics (NASDAQ:FULC) issued its quarterly earnings results on Tuesday. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31), Zacks reports.

Fulcrum Therapeutics Trading Down 1.0%

Shares of NASDAQ FULC opened at $10.89 on Tuesday. Fulcrum Therapeutics has a one year low of $2.32 and a one year high of $15.74. The business has a 50-day moving average price of $10.87 and a two-hundred day moving average price of $9.47. The firm has a market capitalization of $589.37 million, a PE ratio of -9.23 and a beta of 3.19.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus set a $25.00 price objective on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Wall Street Zen lowered shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $23.00 price target (up previously from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Royal Bank Of Canada raised their price objective on Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Monday, December 8th. Finally, The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.11.

Insider Buying and Selling

In related news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider directly owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the transaction, the director directly owned 469,864 shares in the company, valued at $5,577,285.68. The trade was a 3.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of Fulcrum Therapeutics

Institutional investors have recently bought and sold shares of the company. Quarry LP acquired a new stake in shares of Fulcrum Therapeutics during the 3rd quarter valued at about $35,000. Meeder Asset Management Inc. acquired a new position in shares of Fulcrum Therapeutics during the 4th quarter worth about $39,000. Russell Investments Group Ltd. boosted its stake in Fulcrum Therapeutics by 4,209.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after purchasing an additional 9,092 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Fulcrum Therapeutics in the 4th quarter valued at approximately $75,000. Finally, Evergreen Capital Management LLC bought a new position in Fulcrum Therapeutics in the 2nd quarter worth approximately $114,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.